Protagenic Therapeutics declares rights offering at $0.01 per share to preserve ownership after Phytanix acquisition

Protagenic Therapeutics, Inc.new

Board authorized distribution of one Right per common share held as of July 7, 2025 record date.
Each Right entitles holder to purchase 4.57 common shares at $0.01 per share, subject to stockholder approval.
Rights become exercisable only after stockholder meeting approves Phytanix acquisition and share issuance; exercisable for up to 6 months.
Rights initially trade with Common Stock, become separable after approval; Rights Agreement with Equiniti Trust Company.

item 3.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.